phrykt

Tarsus Pharmaceuticals, Inc. (TARS): who owns it and who trades it

As of Nov 16, 2026, TARS insiders reported 59 open-market sales worth $20M and no purchases in the last 12 months, with 64% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bobak R. Azamian (CEO), with $5.2M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Tarsus Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TARS

256 funds and institutions reported TARS shares worth $3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.9.0%
Deep Track Capital, LP8.5%
Rtw Investments, LP7.8%
Jupiter Topco LLC6.5%
Paradigm Biocapital Advisors LP6.5%
Assenagon Asset Management S.A.4.4%
Morgan Stanley4.2%
Vanguard Capital Management LLC4.2%
Jennison Associates LLC3.9%
Tang Capital Management LLC3.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.3.86M8.96%$243M+9%
Deep Track Capital, LP3.67M8.52%$231M+2%
Rtw Investments, LP3.36M7.80%$211M+0%
Jupiter Topco LLC2.81M6.53%$177M–
Paradigm Biocapital Advisors LP2.78M6.45%$175M+8%
Assenagon Asset Management S.A.1.89M4.40%$119M+48%
Morgan Stanley1.83M4.25%$115M-6%
Vanguard Capital Management LLC1.79M4.17%$113M+2%
Jennison Associates LLC1.66M3.87%$105M-3%
Tang Capital Management LLC1.57M3.65%$98.7M+32%
Millennium Management LLC1.43M3.32%$89.8M+153%
Bank of America Corp1.19M2.77%$75.1M-0%
Geode Capital Management, LLC1.11M2.57%$69.6M-1%
State Street Corp1.07M2.49%$67.5M+10%
Vestal Point Capital, LP1.05M2.44%$66.1M+425%
Invesco Ltd.785,8081.83%$49.5M+6%
Goldman Sachs Group Inc742,6931.73%$46.7M+69%
Frazier Life Sciences Management, L.P.728,6441.69%$45.9MNo change
D. E. Shaw & Co., Inc.710,5591.65%$44.7M-10%
FMR LLC (Fidelity)672,9491.56%$42.4M-8%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TARS insiders reported $0 of open-market purchases and $20M of sales. 64% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$20M
59 trades, 9 people
Sales under a 10b5-1 plan
64%
Share of sale value
Latest trade
Sep 15, 2026
Filed Sep 17, 2026

Purchases and sales by month

$7.9M$7.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 15, 2026William J Phd LinkDirectorSale plan66$80.01$5.3KForm 4
Sep 15, 2026William J Phd LinkDirectorSale plan759$79.00$60KForm 4
Sep 15, 2026William J Phd LinkDirectorSale plan11,675$78.33$915KForm 4
Sep 4, 2026Bobak R. AzamianCEOSale plan2,900$91.27$265KForm 4
Sep 4, 2026Bobak R. AzamianCEOSale plan7,100$90.27$641KForm 4
Sep 4, 2026Elizabeth Yeu LinChief Medical OfficerSale plan1,590$85.00$135KForm 4
Sep 4, 2026Elizabeth Yeu LinChief Medical OfficerSale plan1,590$90.00$143KForm 4
Sep 4, 2026Elizabeth Yeu LinChief Medical OfficerSale plan5,387$85.00$458KForm 4
Sep 4, 2026Elizabeth Yeu LinChief Medical OfficerSale plan5,386$90.00$485KForm 4
Sep 4, 2026Seshadri NeervannanChief Operating OfficerSale plan4,564$85.00$388KForm 4
Sep 2, 2026Bobak R. AzamianCEOSale plan10,000$80.06$801KForm 4
Sep 2, 2026Elizabeth Yeu LinChief Medical OfficerSale plan1,590$80.00$127KForm 4
Sep 2, 2026Elizabeth Yeu LinChief Medical OfficerSale plan5,387$80.00$431KForm 4
Sep 1, 2026Elizabeth Yeu LinChief Medical OfficerSale plan4,601$73.86$340KForm 4
Jun 17, 2026Bobak R. AzamianCEOSale plan5,418$61.81$335KForm 4
Jun 17, 2026Bobak R. AzamianCEOSale plan4,582$61.24$281KForm 4
Jun 16, 2026Jeffrey S FarrowSee RemarksSale14,396$60.95$877KForm 4
Jun 15, 2026Katherine GoodrichDirectorSale plan2,954$62.08$183KForm 4
Jun 15, 2026William J Phd LinkDirectorSale plan10,572$61.97$655KForm 4
Jun 15, 2026William J Phd LinkDirectorSale plan1,928$62.94$121KForm 4
Mar 20, 2026Seshadri NeervannanChief Operating OfficerSale plan2,989$66.75$200KForm 4
Mar 19, 2026Dianne C. WhitfieldChief Human Resources OfSale4,174$67.00$280KForm 4
Mar 19, 2026Bryan WahlGeneral CounselSale4,231$67.00$283KForm 4
Mar 19, 2026Seshadri NeervannanChief Operating OfficerSale4,589$67.00$307KForm 4
Mar 19, 2026Aziz MottiwalaChief Commercial OfficerSale4,440$67.00$297KForm 4
Mar 19, 2026Elizabeth Yeu LinChief Medical OfficerSale390$67.00$26.1KForm 4
Mar 19, 2026Jeffrey S FarrowSee RemarksSale2,186$67.00$146KForm 4
Mar 19, 2026Bobak R. AzamianCEOSale11,964$67.00$802KForm 4
Mar 18, 2026Dianne C. WhitfieldChief Human Resources OfSale4,071$68.71$280KForm 4
Mar 18, 2026Bryan WahlGeneral CounselSale4,125$68.71$283KForm 4
Mar 18, 2026Seshadri NeervannanChief Operating OfficerSale3,610$68.71$248KForm 4
Mar 18, 2026Aziz MottiwalaChief Commercial OfficerSale4,330$68.71$298KForm 4
Mar 18, 2026Elizabeth Yeu LinChief Medical OfficerSale379$68.71$26KForm 4
Mar 18, 2026Jeffrey S FarrowSee RemarksSale2,133$68.71$147KForm 4
Mar 18, 2026Bobak R. AzamianCEOSale11,667$68.71$802KForm 4
Mar 17, 2026Dianne C. WhitfieldChief Human Resources OfSale4,029$69.42$280KForm 4
Mar 17, 2026Bryan WahlGeneral CounselSale4,084$69.42$284KForm 4
Mar 17, 2026Seshadri NeervannanChief Operating OfficerSale3,125$69.42$217KForm 4
Mar 17, 2026Aziz MottiwalaChief Commercial OfficerSale4,286$69.42$298KForm 4
Mar 17, 2026Elizabeth Yeu LinChief Medical OfficerSale375$69.42$26KForm 4
Mar 17, 2026Jeffrey S FarrowSee RemarksSale2,111$69.42$147KForm 4
Mar 17, 2026Bobak R. AzamianCEOSale10,972$69.42$762KForm 4
Mar 16, 2026William J Phd LinkDirectorSale plan8,378$69.03$578KForm 4
Mar 16, 2026William J Phd LinkDirectorSale plan493$69.75$34.4KForm 4
Mar 16, 2026William J Phd LinkDirectorSale plan3,629$68.09$247KForm 4
Mar 4, 2026Seshadri NeervannanChief Operating OfficerSale plan8,366$76.67$641KForm 4
Jan 2, 2026Dianne C. WhitfieldChief Human Resources OfSale plan835$81.90$68.4KForm 4
Jan 2, 2026Dianne C. WhitfieldChief Human Resources OfSale plan893$82.93$74.1KForm 4
Jan 2, 2026Dianne C. WhitfieldChief Human Resources OfSale plan8,122$80.71$656KForm 4
Jan 2, 2026Dianne C. WhitfieldChief Human Resources OfSale plan5,715$80.09$458KForm 4
Dec 24, 2025Bobak R. AzamianCEOSale plan5,443$82.41$449KForm 4
Dec 24, 2025Bobak R. AzamianCEOSale plan557$83.54$46.5KForm 4
Dec 16, 2025Dianne C. WhitfieldChief Human Resources OfSale plan7,397$80.10$592KForm 4
Dec 16, 2025Elizabeth Yeu LinChief Medical OfficerSale2,078$79.50$165KForm 4
Dec 15, 2025William J Phd LinkDirectorSale plan5,046$80.80$408KForm 4
Dec 15, 2025William J Phd LinkDirectorSale plan1,148$82.39$94.6KForm 4
Dec 15, 2025William J Phd LinkDirectorSale plan5,680$80.71$458KForm 4
Dec 15, 2025William J Phd LinkDirectorSale plan4,766$81.50$388KForm 4
Dec 15, 2025William J Phd LinkDirectorSale plan6,306$81.75$516KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bobak R. AzamianPresident/CEO and Board Chair, Director–$5.2MSep 4, 2026
William J Phd LinkDirector–$4.5MSep 15, 2026
Dianne C. WhitfieldChief Human Resources Officer–$2.7MMar 19, 2026
Elizabeth Yeu LinChief Medical Officer–$2.4MSep 4, 2026
Seshadri NeervannanChief Operating Officer–$2MSep 4, 2026
Jeffrey S FarrowSee Remarks–$1.3MJun 16, 2026
Aziz MottiwalaChief Commercial Officer–$893KMar 19, 2026
Bryan WahlGeneral Counsel–$850KMar 19, 2026
Katherine GoodrichDirector–$183KJun 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TARS short interest

High short interest. 12.3% of TARS shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 24%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.07M TARS shares were sold short, 12.3% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 874,486 shares, buying them all back would take about 6.9 trading days (days to cover).

Shares short, % of all shares

12.3%May 15Oct 3014.3%

Days to cover

6.9May 15Oct 3010.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.07M12.30%+6%874,4866.9
Oct 15, 20265.73M13.06%-6%1.00M5.7
Sep 30, 20266.07M13.83%-1%732,0128.3
Sep 15, 20266.13M13.96%+2%923,4266.6
Aug 31, 20266.01M13.70%+0%613,1559.8
Aug 14, 20266.00M13.67%-0%801,0937.5
Jul 31, 20266.02M13.71%+4%914,4206.6
Jul 15, 20265.78M13.44%-2%1.82M3.2
Jun 30, 20265.89M13.69%+18%943,1866.2
Jun 15, 20264.98M11.57%-3%559,3348.9
May 29, 20265.13M11.91%+4%690,0817.4
May 15, 20264.91M11.40%+2%855,8355.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Tarsus Pharmaceuticals company events

Tarsus Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Sep 10, 2026DealTarsus Pharmaceuticals, Inc. completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a Delaware corporation, pursuant to that certain Agreement and Plan of Merger, dated as of July 31, 2026, by and among the Company, Alkeus, Apex 2026 Merger Sub, Inc., a Delaware corporation… Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Aug 6, 2026AgreementTarsus Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with a syndicate of existing and new healthcare investors for a private placement of: (i) 2,098,519 shares of common stock, par value $0.0001 per share, of the Company, at a purchase price of $56.00 per share; and (ii)… Filing
  5. Aug 6, 2026AgreementTarsus Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with Alkeus Pharmaceuticals, Inc., a Delaware corporation, Apex 2026 Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, and Shareholder Representative Services LLC, as the securityholders’… Filing
  6. Jul 13, 2026LeadershipTarsus Pharmaceuticals, Inc. announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company. Filing
  7. Jul 8, 2026AgreementTarsus Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with iRenix Medical, Inc., a Delaware corporation, Dolores Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company and Fortis Advisors LLC, as the securityholders’ representative. Filing
  8. Jun 29, 2026VoteReported shareholder vote results. Filing
  9. May 6, 2026ResultsReleased financial results. Filing
  10. Feb 23, 2026ResultsReleased financial results. Filing
  11. Feb 18, 2026LeadershipThe Board of Directors of Tarsus Pharmaceuticals, Inc., upon the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Board from seven to eight directors and appointed David E.I. Pyott to the Board, effective immediately. Filing
  12. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Tarsus Pharmaceuticals financials

Famous investors that hold TARS

4 of the 50 well-known investors we track reported holding TARS in their latest 13F filing. The largest position is Israel Englander's, worth $85.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.09M$85.5M0.1%-23%
Ken Griffin · Citadel AdvisorsQ3 2026109,170$8.2M0.0%-55%
Steve Cohen · Point72 Asset ManagementQ3 202685,000$6.7M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202672,100$5.7M0.0%+675%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TARS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Paradigm BioCapital Advisors LP13G/A4.7%
Nov 16, 2026Paradigm BioCapital Advisors LP13G/A4.7%
Nov 5, 2026FMR LLC13G6.4%
Nov 5, 2026FMR LLC13G6.4%

Questions about Tarsus Pharmaceuticals, Inc. (TARS) stock

Who owns the most TARS stock?

The largest reported owner of Tarsus Pharmaceuticals, Inc. (TARS) is BlackRock, Inc., with 9.0% of the company. In total, 256 funds and institutions reported holding TARS at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are TARS insiders buying or selling?

In the last 12 months, TARS insiders reported no open-market purchases and 59 sales worth $20M. The latest trade was on Sep 15, 2026. See every trade.

What is the short interest in TARS?

As of Oct 30, 2026, 6.07M TARS shares were sold short, 12.3% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 874,486 shares, buying them all back would take about 6.9 trading days (days to cover). See the history.

Which famous investors hold TARS?

4 of the 50 well-known investors we track reported TARS in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $85.5M. See all holders.

Executive pay

Tarsus Pharmaceuticals's chief executive was paid a total of $6.6M for the year ended Dec 31, 2025, down 16% from $7.9M the year before. In the last 12 months, Tarsus Pharmaceuticals's executives and directors bought no stock on the open market and sold $20M.

Chief executive, total pay$6.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$31.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.